| Literature DB >> 35053854 |
Kristina Rosqvist1,2, Anette Schrag3, Per Odin1,2.
Abstract
Parkinson's disease (PD) is a chronic, progressive, neurodegenerative disease involving both motor and non-motor symptoms (NMS). In the late stage of the disease, Hoehn and Yahr (HY) stages IV-V, the symptomatology is often severe and patients become increasingly dependent on help in their daily life, resulting in an increased burden for the informal caregivers. To assess the implications of the caregiver burden, caregiver quality of life (QoL) was assessed in 74 informal caregivers to patients in late stage PD, by the Alzheimer's Patient Partners Life Impact Questionnaire (APPLIQue), which has been found useful also in PD. The majority of caregivers were the spouse/partner. Individual items provided information on which aspects of caregiver burden were the most common, i.e., items: "feel guilty if not there" (71% affirmed), "situation wears me down" (65% affirmed) and "always on my mind" (61% affirmed). In simple linear regression analyses, female patient gender (p = 0.007), better cognition (p = 0.004), lower NMS burden (p = 0.012) and not being the partner (p = 0.022) were associated with better caregiver QoL. Multivariable linear regression analyses identified better cognition (p = 0.004) and female patient gender (p = 0.035) as independently associated with better informal caregiver QoL. Identifying and treating NMS as well as recognizing and alleviating caregiver burden seem essential to enhance QoL for both patients and caregivers in late stage PD.Entities:
Keywords: Parkinson’s disease; caregiver burden; informal caregiver; late stage
Year: 2022 PMID: 35053854 PMCID: PMC8773513 DOI: 10.3390/brainsci12010111
Source DB: PubMed Journal: Brain Sci ISSN: 2076-3425
Descriptive characteristics of patient data and in relation to informal caregiver self-reported QoL in late stage PD (APPLIQue), n = 74.
| Variables | Patient Data | APPLIQue Score |
|---|---|---|
| ( | (Median, q1–q3) | |
| Age (year), median (q1–q3) | 78 (73–84) | |
| PD duration, median (q1–q3) | 15 (11–19) | |
| Gender | ||
| Male | 62 (58%) | 8 (5–15) |
| Female | 45 (42%) | 3 (0–10) |
| Partner, | 65 (61%) | |
| Dwelling place | ||
| Home | 67 (63%) | 8 (3–15) |
| Nursing home | 40 (37%) | 7 (3–11) |
| Hoehn and Yahr stage | ||
| IV | 79 (74%) | 7 (3–12) |
| V | 28 (26%) | 9 (4–16) |
| ADL independency (S&E), median (q1–q3) | 40 (30–50) | |
| Home health care, | ||
| No | 18 (17%) | 6 (3–12) |
| Yes | 89 (83%) | 8 (3–14) |
| Cognition (MMSE), median (q1–q3) | 22 (18–27) * | |
| Cognitive impairment ≤ 23 | 60 (58%) | 8 (6–14) |
| No cognitive impairment ≥ 24 | 43 (42%) | 3 (0–9) |
| Depressive symptoms, GDS-30 | 11 (8–16) *** | |
| No depression (<10) | 38 (38%) | 6 (3–14) |
| Depression (≥10) | 62 (62%) | 8 (2–11) |
| Motor function (UPDRS III total score) | 40 (29–53) | |
| Less symptoms (first and second quartiles) | 7 (3–11) | |
| More symptoms (third and fourth quartiles) | 8 (3–14) | |
| Non-motor symptomatology (NMSS total score) | 91 (55–128) ** | |
| Less symptoms (first and second quartiles) | 6 (0–14) | |
| More symptoms (third and fourth quartiles) | 8 (5–12) | |
| Hallucinations (NMSS item 13), median (q1–q3) | 0 (0–4) | |
| Not present | 58 (54%) | |
| Mild (1–5) | 31 (29%) | 7 (3–12) |
| Moderate/severe (≥6) | 18 (17%) | 11 (3–15) |
| Delusions (NMSS item 14), median (q1–q3) | 0 (0–1) | |
| Not present | 80 (75%) | |
| Mild (1–5) | 14 (13%) | 8 (3–13) |
| Moderate/severe (≥6) | 13 (12%) | 5 (0–13) |
| APPLIQue total score, median (q1–q3) | 8 (3–12) | |
| Partner | 8 (4–14) | |
| Daughter/son/sibling | 2 (0–8) |
PD, Parkinson’s disease; APPLIQue, the Alzheimer’s Patient Partners Life Impact Questionnaire (score range 0–25, higher = worse); q1–q3, first and third quartiles; HY, Hoehn and Yahr staging scale (score range I-V, higher = worse); S&E, Schwab & England Activities of Daily Living (ADL) scale (score range 0–100, higher = better); MMSE, Mini-mental state examination (score range 0–30, higher = better); UPDRS III, Unified PD Rating Scale, part III = motor examination (score range 0–108, higher = worse); NMSS, Non-Motor Symptoms Scale (0–360, higher = worse); GDS-30, Geriatric Depression Scale (score range 0–30, higher = worse). * 4 missing; ** 2 missing; *** 7 missing.
Figure 1Self-reported quality of life of informal caregivers to patients in late stage Parkinson’s disease (APPLIQue 25 items; response alternatives yes/no), n = 74. Frequencies of informal caregivers responding yes (%).
Simple linear regression analyses with APPLIQue as the dependent variable, n = 74.
| Independent Variables | Unstandardized | Standardized | |
|---|---|---|---|
| Coefficient β (95% CI) | Coefficient β | ||
| Patient data | |||
| Age (year) | −0.198 (−0.400 to 0.003) | −0.225 | 0.053 |
| PD duration | −0.141 (−0.336 to 0.054) | −0.167 | 0.155 |
| Patient gender (ref = male) | −3.935 (−6.744 to −1.125) | −0.313 |
|
| Partner | 4.017 (0.603 to 7.431) | 0.266 |
|
| Dwelling place (home vs. nursing home) | −1.252 (−4.195 to 1.691) | −0.099 | 0.399 |
| Hoehn and Yahr stage | 1.200 (−2.106 to 4.507) | 0.085 | 0.472 |
| ADL independency (S&E) | −0.022 (−0.126 to 0.082) | −0.05 | 0.674 |
| Home health care (yes) | 0.950 (−2.427 to 4.328) | 0.066 | 0.577 |
| Cognition, MMSE | −0.088 (−0.324 to 0.148) | −0.09 | 0.458 |
| Cognitive impairment (dichotomized 0–23 vs. 24–30) | −4.271 (−7.135 to −1.407) | −0.337 |
|
| Depressive symptoms (GDS-30) | −0.065 (−0.295 to 0.166) | −0.069 | 0.578 |
| Depression (dichotomized 0–9 vs. 10–30) | −0.561 (−3.549 to 2.428) | −0.046 | 0.709 |
| Motor function (UPDRS III total score) | 0.039 (−0.053 to 0.132) | 0.099 | 0.399 |
| Non-motor symptomatology (NMSS total score) | 0.036 (0.008 to 0.065) | 0.292 |
|
| Hallucinations (NMSS item 13) | 0.206 (−0.209 to 0.621) | 0.116 | 0.325 |
| Hallucinations (dichotomized 0 vs. ≥ 1) | 1.368 (−1.531 to 4.267) | 0.11 | 0.350 |
| Delusions (NMSS item 14) | 0.089 (−0.546 to 0.723) | 0.033 | 0.781 |
| Delusions (dichotomized 0 vs. ≥ 1) | 1.167 (−2.364 to 4.698) | 0.077 | 0.512 |
CI, confidence interval; PD, Parkinson’s disease; APPLIQue, the Alzheimer’s Patient Partners Life Impact Questionnaire (score range 0–25, higher = worse); q1–q3, first and third quartiles; ref, reference category; HY, Hoehn and Yahr staging scale (score range I-V, higher = worse); ADL, activities of daily living; S&E, Schwab and England ADL scale (score range 0–100, higher = better); MMSE, Mini-mental state examination (score range 0–30, higher = better); NMSS, Non-Motor Symptoms Scale (0–360, higher = worse); GDS-30, Geriatric Depression Scale (score range 0–30, higher = worse); UPDRS III, Unified PD Rating Scale, part III = motor examination (score range 0–108, higher = worse). Bold p-values are statistically significant at p < 0.05.
Multivariable linear regression analyses with APPLIQue as the dependent variable, n = 70.
| Independent Variables | Unstandardized | Standardized | |
|---|---|---|---|
| Coefficient β (95% CI) | Coefficient β | ||
| Patient data | |||
| Cognitive impairment (MMSE dichotomized 0–23 vs. 24–30) | −4.139 (−6.880 to −1.397) | −0.327 |
|
| Patient gender (ref = male) | −2.877 (−5.545 to −0.209) | −0.236 |
|
| Age | −0.164 (−0.349 to 0.022) | −0.193 | 0.082 |
CI, confidence interval; PD, Parkinson’s disease; APPLIQue, the Alzheimer’s Patient Partners Life Impact Questionnaire (score range 0–25, higher = worse). MMSE, Mini-mental state examination (score range 0–30, higher = better). Ref = reference category. Bold p-values are statistically significant at p < 0.05. Adjusted R2 = 0.184. Independent variables entered in the multivariable linear regression model (backward method): age, gender, PD duration, partner, cognitive impairment (MMSE dichotomized at 23/24) and total NMS burden (NMSS total score).